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Abstract
Background: Key features of advanced ovarian cancer include metastasis via cell clusters in the abdominal cavity
and increased chemoresistance. Resveratrol and derivatives of resveratrol have been shown to have antitumour
properties. The purpose of this study was to investigate the effect of resveratrol and acetyl-resveratrol on 3D cell
aggregates of ovarian cancer, and establish if NF-κB signalling may be a potential target.
Methods: Poly-HEMA coated wells were used to produce 3D aggregates of two ovarian cancer cell lines, SKOV-3
and OVCAR-5. The aggregates were exposed to 10, 20 or 30 μM resveratrol or acetyl-resveratrol for 2, 4 or 6 days.
Cell growth and metabolism were measured then ELISA, western blot and immunofluorescence were utilised to
evaluate VEGF, IL-8 and NF-κB levels.
Results: Resveratrol and acetyl-resveratrol reduced cell growth and metabolism of SKOV-3 aggregates in a dose-
and time-dependent manner. After 6 days all three doses of both compounds inhibited cell growth. This growth
inhibition correlated with the attenuated secretion of VEGF and a decrease of NF-κB protein levels. Conversely, the
secretion of IL-8 increased with treatment. The effects of the compounds were limited in OVCAR-5 cell clusters.
Conclusions: The results suggest that resveratrol and its derivative acetyl-resveratrol may inhibit in vitro 3D cell
growth of certain subtypes of ovarian cancer, and growth restriction may be associated with the secretion of VEGF
under the control of the NF-κB protein.
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Background
Ovarian cancer is a lethal gynaecological cancer and is
the seventh most common cause of cancer death among
women [1]. The majority of women present with an ad-
vanced stage of the disease [2]. The current treatment
options of debulking surgery and chemotherapy are gen-
erally not curative in advanced stages of the disease due
to recurrence and chemoresistance [3]. Therefore, alter-
native treatments that target cancer cells, reduce tumour
growth and increase tumour-free survival are of great
importance.
Ovarian cancer metastasises via the fluid in the peri-
toneal cavity. Cells slough off the primary tumour and
form small 3D clusters or aggregates in the peritoneal
fluid. The accumulation of peritoneal fluid, which is
known as ascites, is often associated with advanced ovar-
ian cancer and correlates with poor prognosis [4]. The
microenvironment of the ascitic fluid is rich in a wide
range of growth factors and cytokines, and these are
believed to sustain cell cluster survival, growth and sec-
ondary site establishment [5]. Relatively little is known,
however, about the interactions between ascitic fluid
components and the 3D aggregates. The 3D aggregates
of ovarian cancer cells are integral to metastasis, and are
possibly involved with the development of chemoresis-
tance [6]. Few studies have investigated the use of
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potential therapeutic agents against the 3D aggregates of
ovarian cancer.
Our knowledge of ovarian cancer aggregate survival in
ascitic fluid is limited. However, studies on other types
of solid tumour, coupled with analyses of pertinent
proteins suggest that angiogenic and inflammatory medi-
ators may play a significant role. Of the numerous pro-
angiogenic cytokines vascular endothelial growth factor
(VEGF) is one of the most well described. In addition to
being a key regulator of angiogenesis, it also enhances
cell survival, proliferation and migration [7, 8]. Studies
have revealed that VEGF is over expressed by ovarian
cancer [9, 10]. Interleukin-8 (IL-8) is another regulation
protein involved in tumorigenic activities in cancers, and
has been reported to be over expressed in ovarian cancer
[11–13], suggesting its importance to ovarian cancer
carcinogenesis.
There is evidence that VEGF and IL-8 expression in
ovarian cancer are under the transcriptional control of
nuclear factor kappaB (NF-κB) [14]. The NF-κB family
of transcription factors are activated via two signalling
pathways [15]. In normal cells, NF-κB activation is very
tightly regulated, but constitutive activation has been
identified in a range of cancers [16–18] suggesting that
NF-κB signalling may be important in cancer survival.
Furthermore, in some cancer types the activation of NF-
κB correlates with the expression of VEGF [19] and IL8
[20]. However, this correlation is not well understood in
ovarian cancer.
The polyphenol resveratrol is a possible inhibitor of
the NF-κB signalling pathway in ovarian cancer. Resvera-
trol is one of the major antioxidants found in the skin of
red grapes and has anti-inflammatory [21], cardioprotec-
tive [22] and anti-carcinogenic properties [23]. It has
been linked to the inhibition of NF-κB in prostate [24]
and lung cancer [25], and the down regulation of VEGF
[26] and IL-8 [27]. However, there have been no reports
on the effects of resveratrol on NF-κB activity, cytokine
expression or their correlation with the growth of ovar-
ian cancer clusters.
Although resveratrol appears to be a very promising
cancer treatment, it has low bioavailability [28, 29], be-
cause of this the resveratrol derivative acetyl-resveratrol
has aroused interest. In chemopreventive and chemo-
therapeutic studies, it appears to possess the same char-
acteristics as resveratrol, but may not undergo such
rapid metabolism in the liver and with increased cellular
uptake may have greater bioavailability [30]. The hy-
droxyl groups of resveratrol are acetylated in acetyl-
resveratrol which accounts for it being a more stable
compound and increased uptake in the body [31].
In the present study, we examined the effect of resver-
atrol and acetyl-resveratrol on cell growth and on the
production of regulatory factors in 3D aggregates of two
ovarian cancer cell lines. Our data shows that both com-
pounds significantly inhibit cell growth, VEGF secretion
and NF-κB activation in a time-, dose- and cell line
dependent manner. The secretion of IL-8 increased.
Methods
Cell culture
The human ovarian adenocarcinoma cell lines SKOV-3
and OVCAR-5 were obtained from Dr. Judith McKenzie,
Haematology Research group, University of Otago,
Christchurch, New Zealand. Both cell lines were main-
tained in Dulbecco’s Modified Eagle Medium (GIBCO®,
Life Technologies, New Zealand), supplemented with
10% fetal bovine serum (GIBCO®, Life Technologies,
New Zealand), PenStrep (GIBCO®, Life Technologies,
New Zealand) at a working concentration of 100 units/
ml penicillin and 100 μg/ml streptomycin, 2 mM Gluta-
MAX™ (GIBCO®, Life Technologies, New Zealand) and 2
μg/ml Fungizone® (Life Technologies, New Zealand).
The supplemented media is henceforth referred to as
working media. SKOV-3 and OVCAR-5 cells in working
media were continuously maintained in a culture flask at
37 °C in a humidified 5% CO2 atmosphere incubator.
Production of 3D aggregates
To prevent adhesion of cells to culture plates, 12-well
culture plates were pre-coated with 24 mg/ml Polyhy-
droxyethylmethacrylate (poly-HEMA) (Sigma, New
Zealand) prior to cell culturing (0.5 ml/well). Prior to
coating, poly-HEMA was fully dissolved in 95% ethanol
at a concentration of 24 mg/ml and was heated to ap-
proximately 70 °C. After the poly-HEMA was placed in
the wells the plates were left overnight at 37 °C on an
orbital shaker. Prior to cell culture, the coated wells were
washed once with PBS at pH 7.4. To detach the cell
monolayer of the SKOV-3 and OVCAR-5 cell lines from
the flask surface, they were incubated with 1x trypsin-
EDTA for 20–30 min. Cells were counted with a haemo-
cytometer to determine the concentration of the cells in
suspension. Cells were then plated at a density of
200,000 cells/well and were incubated at 37 °C in a
humidified 5% CO2 atmosphere for 6 days. Over this
time the cells became clusters and aggregates. Working
media was refreshed every 2 days with 1 ml of fresh
working media.
Treatment with resveratrol, acetyl-resveratrol and Bay
11-7085
Resveratrol and acetyl-resveratrol were provided by
Dr. Saurabh Shah, Biotivia (USA). A NF-κB inhibitor,
Bay 11-7085, was purchased Sigma-Aldrich (Auckland,
New Zealand). Resveratrol was dissolved in a 50:50
combination of PBS and DMSO, acetyl-resveratrol
and Bay 11-7085 were dissolved in 100% DMSO.
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Fresh working media containing the relevant com-
pounds (at concentrations of 10, 20 and 30 μM) was
replaced every 2 days for up to 6 days. Thus, at the
endpoint of culturing the cells had a total incubation
time of 8, 10 or 12 days respectively; 6 days develop-
ing the aggregates and 2, 4 or 6 days of treatment.
For all experiments, the final concentration of DMSO
used in controls was the concentration of DMSO that
was present in the 30 μM treatments. At least 4 inde-
pendent experiments were carried out for each treat-
ment and within each experiment there were 3
replicates.
Growth determination using the crystal violet assay
Growth of the 3D aggregates was quantified indirectly
using crystal violet staining. In brief, cell aggregates were
isolated and incubated with 1x trypsin-EDTA for 20 min
at 37 °C. Cells were washed twice with PBS (pH 7.4)
and were incubated for a further 15 min at 37 °C
with 2 mg/ml crystal violet in 2% (v/v) ethanol in
milliQ water. The cells were then washed with milliQ
water to remove unbound crystal violet, and were iso-
lated by centrifugation at 1500 rpm for 5 min. The
supernatant was removed and the process repeated 3
times until the supernatant was colourless. Cells were
then lysed in 10% (w/v) sodium dodecyl sulphate
(SDS) solution. 200μl of the homogenous cell lysate
was then loaded onto a 96-well plate. The optical
density was determined at 560 nm (OD560) using a
microplate reader (SpectraMax M5, Molecular
Devices).
Cellular metabolism determination using the Alamar blue
assay
On the 6th day of treatment with compounds, 0.5 ml
media was removed from each well and 50 μl of Alamar
blue dye (ThermoFisher Scientific, New Zealand) added
to cell aggregates. Aggregates were incubated at 37 °C
with the dye for 4 h after which 200 μl of media from
each well was transferred to a 96-well plate. The absorb-
ance at 570 and 600 nm was measured using a micro-
plate reader (SpectraMax M5, Molecular Devices).
Cellular metabolism was calculated from the difference
of absorbance at 600 and 570 nm.
Detection of vascular endothelial growth factor (VEGF)
and interleukin-8 (IL-8)
The conditioned media of the control and treated cells
(2, 4 or 6 days) was used to determine secreted VEGF
and IL-8 levels. The conditioned media were centrifuged
at 1500 rpm to remove cell debris and stored at -80 °C
until assayed using the DuoSet Human VEGF ELISA kit
(R&D System, New Zealand) and the DuoSet Human
IL-8 ELISA kit (R&D System, New Zealand). The assays
were carried out according to the manufacturer’s in-
structions. Samples were diluted 50%, the amount of
VEGF or IL-8 was determined by comparing absorbance
of each well to a standard curve and corrected for total
protein.
Western blotting
Cell aggregates were harvested after their respective
treatments by centrifugation at 1500 rpm for 5 min and
the cell pellet was resuspended in cold RIPA buffer con-
taining protease inhibitor cocktail tablets (Complete
Mini, Roche, New Zealand). The cell lysates were left on
ice for 30 min to ensure total cell lysis. Total protein
was determined using a Pierce™ BCA protein assay kit
(ThermoFisher Scientific, New Zealand) according to
the manufacturer’s instructions. Sample buffer (0.2% (v/
v) bromophenol blue, 25% (v/v) glycerol, 10% SDS in
Tris-HCl and pH 6.8) was added and protein lysates
were boiled for 10 min. Samples (10 μg protein) were
fractionated in 5–12% SDS-PAGE gels and transferred
to PDVF membranes (Bio-Rad Laboratories, Hercules,
USA). The markers used were MagicMark Western Pro-
tein Standard (Thermofisher, New Zealand) and Preci-
sion Plus Protein Standard (Bio-Rad, Hercules, New
Zealand). The membranes were blocked for 60 min with
either 5% (w/v) nonfat skim milk (Pams brand, New
World, New Zealand) or 1% (w/v) bovine serum albumin
(ThermoFisher Scientific, New Zealand) in 1% tween-
TBS. Antibodies were diluted to 1/500 to 1/1000 with
the appropriate blocking solution, and membranes were
incubated with primary antibodies overnight at 4 °C.
Membranes were developed using either donkey anti-
mouse IgG-AP or goat anti-rabbit IgG-AP secondary
antibodies (Santa Cruz, CA, USA, 1:10,000). Antibody
localisation was determined using a chemiluminescent
detection kit (Amersham ECL Prime Western Blotting
Detection Reagent Kit, GE Healthcare) and the bands vi-
sualized using Alliance 4.7, Unitec (Cambridge, UK).
The primary antibodies used were PCNA (sc-25280),
pIκBα (sc-8404), NF-κB (sc-372), pNF-κB (sc-33020) and
GAPDH (sc-25778), all purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA).
Immunofluorescence
Cell aggregates were harvested after treatments, they
were then centrifuged and the supernatant removed. 1
ml of ice cold mixture of methanol:acetone (50:50% (vol/
vol)) solution was added to the OVCAR-5 and SKOV-3
cell aggregates and the samples were stored at −20 °C
until analysis. Prior to sectioning, SKOV-3 aggregates
were stained with the aniline blue dye solution (1% in
water (Sigma-Aldrich LTD, New Zealand)) for 20 min
and washed with PBS twice. The stained SKOV-3 aggre-
gates were then imbedded in CryO-Z-T solution (Ted
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Pella Inc., USA) and frozen overnight at -80 °C. SKOV-3
samples were then sectioned into 7 μM thick slices,
two slices were placed on appropriately labelled
Superfrost plus slides (Menzel-glaser, Germany), 6
slices per sample were collected, and stored at -20 °C
until analysis.
The OVCAR-5 cell clusters were removed from the
methanol/acetone solution, washed with PBS pH 7.4 and
placed onto slides. Slides of both cell lines were dried
and blocking buffer added for 1 h at room temperature.
Primary antibodies to detect NF-κB or pNF-κB proteins
were diluted to 1:200 in 2% BSA in PBS, added to the
slides and the slides were incubated overnight at 4 °C.
The secondary antibody goat anti-rabbit IgG conjugated
with Atto 594 nm (Sigma-Aldrich LTD, New Zealand,
1:1000) was added to slides which were then incubated
for 1 h at 37 °C, and then samples were stained with
10 μg/ml Hoechst (Invitrogen, New Zealand) for 20
min. The slides were washed extensively with PBS +
0.1% Tween-20, pH 7.4. Cells were observed and im-
aged with an epifluorescence microscope (AxioVision
4.5. Apotome software, Carl Zeiss, Oberkochen,
Germany).
Statistical analysis
At least four independent experiments were carried out
for each treatment and these were statistically analyzed
using GraphPad Prism software (La Jolla, CA, USA). p <
0.05 was considered to indicate statistical significance
determined by one way ANOVA. All data are presented
as mean ± SEM.
Results
Attenuation of cellular growth and metabolism by
resveratrol and acetyl-resveratrol
It has been previously shown that resveratrol reduces
the growth of monolayer and clusters of ovarian can-
cer cell lines [32]. We further examined this in 3D
cell aggregates using concentrations of resveratrol and
acetyl-resveratrol that were closer to levels found in
human serum [29], using the Alamar blue dye assay
(Fig. 1). The metabolism of the SKOV-3 aggregates
was significantly reduced by between 20 and 40%
after 4 and 6 days exposure to resveratrol (Fig. 1a). In
contrast, after 2, 4 and 6 days of treatment the
OVCAR-5 clusters were unaffected (Fig. 1b). Likewise,
acetyl-resveratrol did not have an effect on either cell
line (Fig. 1c and d).
Next, we investigated the effect of the compounds
on cell growth (Fig. 2) by using the crystal violet
assay. SKOV-3 cell growth in 3D cell aggregates was
significantly decreased after 2 and 4 days of treat-
ment with 30 μM resveratrol and after 6 days treat-
ment at all three concentrations tested (Fig. 2a). It
had no effect on growth of OVCAR-5 cell clusters
(Fig. 2b). Similarly, acetyl-resveratrol significantly
decreased the growth of SKOV-3 cells after 6 days
treatment at each of the concentrations tested but
had no effect on the OVCAR-5 cells (Fig. 2c and d).
Both resveratrol and acetyl-resveratrol did not
increase apoptotic cells in both cell lines (data not
shown).
Fig. 1 Cellular metabolism relative to control of SKOV-3 aggregates after treatment with resveratrol (a) or acetyl-resveratrol (c) for 2, 4 or 6 days.
Cellular metabolism relative to control of OVCAR-5 clusters after treatment with resveratrol (b) or acetyl-resveratrol (d) for 2, 4 or 6 days. * indicates
statistical significance p < 0.05 compared to the control. n = 4 independent experiments in triplicate
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Attenuation of Vascular Endothelial Growth Factor (VEGF)
production by resveratrol and acetyl-resveratrol
VEGF is a glycoprotein that is a key regulator of angiogen-
esis. Angiogenesis is fundamental to the development of
solid cancerous tumours as oxygen and nutrients are
required for the cancer to flourish [33]. Elevated levels of
VEGF have been observed in ascitic fluid and these correl-
ate with a poor prognosis [34]. To assess the effect of the
resveratrol and acetyl-resveratrol on the production of
VEGF we used an ELISA. Resveratrol at a concentration of
30 μM reduced VEGF production in SKOV-3 cell aggre-
gates by 41 and 54% after 4 and 6 days respectively (Fig. 3a).
Similar results were observed with acetyl-resveratrol (re-
ductions of 49 and 58% respectively). The basal secretion of
VEGF by OVCAR-5 clusters was much lower than for
SKOV-3 cells, between 0.4 and 1.1 ng/ml/mg (Fig. 3b and
d) and the secretion levels were unchanged in the presence
of both resveratrol (Fig. 3b) and acetyl-resveratrol (Fig. 3d).
Fig. 2 Cell growth relative to control of SKOV-3 aggregates after treatment with resveratrol (a) or acetyl-resveratrol (c) for 2, 4 or 6 days. Cell
growth relative to control of OVCAR-5 clusters after treatment with resveratrol (b) or acetyl-resveratrol (d) for 2, 4 or 6 days. * indicates statistical
significance p < 0.05 compared to the control. n = 4 independent experiments in triplicate
Fig. 3 The secretion of vascular endothelial growth factor (VEGF) of SKOV-3 aggregates after treatment with resveratrol (a) or acetyl-resveratrol (c)
for 2, 4 or 6 days. The secretion of VEGF of OVCAR-5 clusters after treatment with resveratrol (b) or acetyl-resveratrol (d) for 2, 4 or 6 days. * indicates
statistical significance p < 0.05 compared to the control. n = 4 independent experiments in triplicate
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Resveratrol and Acetyl-resveratrol increase the secretion
of Interleukin-8 (IL-8)
The chemokine IL-8 is induced by inflammatory stimuli
and is responsible for activation of neutrophils under
normal conditions [35]. There is evidence of IL-8 sus-
taining cancer cell survival [36] and it is over expressed
in ovarian cancer [13, 37]. We used an ELISA to gauge
the effects of resveratrol and acetyl-resveratrol and
found that the compounds caused an increase in the
production of IL-8 in both cell lines (Fig. 4). Resveratrol
more than doubled the level of IL-8 produced by SKOV-
3’s cell aggregates at all three concentrations after 4 and
6 days (Fig. 4a) and an increasing trend was also ob-
served in OVCAR-5 clusters (Fig. 4b). Acetyl-resveratrol
also had a profound effect on SKOV-3 IL-8 secretion
(Fig. 4c) and again an increasing trend was observed in
OVCAR-5 (Fig. 4d).
Effects of resveratrol and acetyl-resveratrol on the
expression and activation of NF-κB protein
The signalling pathways that control cancer cell survival
and proliferation are of great interest for targeted cancer
cell therapy. There are many cascades involved in cancer
cell growth, but a prominent one, the Nuclear Factor
Kappa B (NF-κB) pathway, has also been linked to the
secretion of VEGF and IL-8 in other cancers such as
breast [19] and prostate cancer [20]. There is also evi-
dence to suggest that resveratrol may attenuate NF-κB
[24]. Therefore, we hypothesised that NF-κB signalling is
a key signalling pathway in ovarian cancer and is a
potential primary target of resveratrol. In order to
investigate the effects of resveratrol and acetyl-
resveratrol on NF-κB protein and its phosphorylation
(pNF-κB), we employed western blotting and immuno-
fluorescence. We stained frozen sections of SKOV-3
aggregates and OVCAR-5 clusters for the heterodimer
NF-κB and pNF-κB. There was an obvious difference in
the abundance of NF-κB and pNF-κB between the two
cell lines, with SKOV-3 expressing a greater amount of
the proteins (Fig. 5). The NF-κB molecule was observed
inside the nucleus (red dots) and cytoplasm of SKOV-3
cells (Fig. 5a). The immunostaining of pNF-κB control
cells was also located inside the nucleus and cytoplasm
with a diffused staining pattern (Fig. 5b). After treatment
with resveratrol (Fig. 5c and d) and acetyl-resveratrol
(Fig. 5e and f) the abundance of both proteins at the
nucleus was reduced. There was a low abundance of
NF-κB and pNF-κB in OVCAR-5 cell clusters (Fig. 5g
and h).
To support the immunofluorescent imaging, we then
examined the expression and activation of NF-κB after 6
days of treatment with the compounds using western
blots. We also investigated two additional proteins that
were known to associate with NF-κB; pIκBα and PCNA.
As shown in Fig. 6, SKOV-3 cell lysates pNF-κB (Fig. 6a
and c) and NF-κB (Fig. 6a and d) showed high expres-
sion which were significantly reduced by resveratrol. In
OVCAR-5 cell lysates, NF-κB expression was much
weaker and unaffected by resveratrol (Fig. 6b and g).and
pNF-κB was not detected (Fig. 6b). pIκBα expression
(Fig. 6b and h) was in contrast much stronger but was
also unaffected by resveratrol. Acetyl-resveratrol at 20
Fig. 4 The secretion of interleukin-8 (IL-8) of SKOV-3 aggregates after treatment with resveratrol (a) or acetyl-resveratrol (c) for 2, 4 or 6 days.
The secretion of IL-8 of OVCAR-5 clusters after treatment with resveratrol (b) or acetyl-resveratrol (d) for 2, 4 or 6 days. * indicates statistical significance
p < 0.05 compared to the control. n = 4 independent experiments in triplicate
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and 30 μM significantly reduced pNF-κB (Fig. 7a and b)
and NF-κB (Fig. 7a and c). pIκBα and PCNA were
unaffected by the presence of resveratrol or acetyl-
resveratrol.
Attenuation of cell growth and VEGF secretion by a NF-κB
inhibitor
To assess if the NF-κB protein is associated with cell
growth, we employed Bay 11-7085, a specific NF-κB in-
hibitor. SKOV3 and OVCAR5 aggregates were treated
for 6 days with inhibitor at the same concentrations as
resveratrol in the previous experiments. Both metabol-
ism and growth of the SKOV3 aggregates was reduced
in a dose dependent fashion by as much as 79 and 52%,
respectively (Fig. 8a and b). The metabolism and growth
of OVCAR5 clusters was also adversely affected, how-
ever, the inhibitor was not as effective. Metabolism de-
creased by only 40% at the most and growth by 28%
(Fig. 8a and b). The secretion of VEGF and IL-8 by
SKOV3 aggregates was also dose-dependently reduced
by the NF-κB inhibitor, 30 μM of the inhibitor decreased
VEGF secretion by 96% and IL-8 by 54% when com-
pared to the control (Fig. 8c and d). Conversely,
OVCAR5 clusters secreted slightly more VEGF and IL-8
when challenged (Fig. 8c and d).
Discussion
Of all the gynaecological cancers ovarian cancer is the
deadliest. It is very difficult to detect, therefore, three
quarters of patients upon diagnosis already have an
advanced stage of the disease. The current treatment
options for this cancer usually become ineffective after a
while and overall survival rates are not good. Finding
alternative treatments and targets related to chemoresis-
tance is of the utmost importance.
Advanced ovarian cancer disseminates via cells in
ascitic fluid, in which the cells survive by aggregating
together [5]. These aggregates then settle at a secondary
location and grow into tumours. The morphology of
metastasising ovarian cancer cells has been implicated in
the development of chemoresistance [6]. Targeting ag-
gregates that are formed by these cells, therefore, could
be very useful in the treatment of ovarian cancer. In this
study, we grew 3D aggregates of the SKOV-3 and
OVCAR-5 cell lines and demonstrate that resveratrol
and acetyl-resveratrol are capable of restricting the
growth and metabolism of the SKOV-3 aggregates in a
time- and dose-dependent manner. We used a 10 μM
dose as this concentration can be found in food products
and is pharmacologically relevant [29]. Previously we
have tested 5, 10, 50 and 100 μM resveratrol and acetyl
resveratrol [32] and found that 50 and 100 μM of both
compounds was able to reduce cell growth and increase
cleaved PARP protein. Therefore, we chose to investigate
20 μM and 30 μM as they are in between the pharmaco-
logically relevant dose and the previously established
effective dose. OVCAR-5 cell clusters showed limited
responses to resveratrol and its derivative.
Fig. 5 Immunofluorescent images of NF-κB and pNF-κB in frozen cut sections of SKOV-3 control aggregates (a and b) treated with resveratrol
(c and d) or acetyl-resveratrol (e and f) for 6 days. NF-κB and pNF-κB in OVCAR-5 control clusters (g and h) treated with resveratrol (i and j) or
acetyl-resveratrol (k and l) for 6 days. NF-κB and pNF-κB were stained red and nuclei were stained blue
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Resveratrol has been shown to be capable of reducing
cancer growth in previous studies [38–41]. However,
these studies use very high doses of the compound, for
example Dann et al [38] used 100 μM and Ji et al [39]
used up to 200 μM. Furthermore, we have measured the
effect of repeat doses over a long time period as we
hypothesised that because of the morphology of the
ovarian cancer aggregates a much longer exposure time
would be required to observe any changes. In contrast,
the majority of the studies done to date have been in
monolayer cultures using high doses of resveratrol and
measuring its effects over short time periods [42–44].
The concentrations of resveratrol and its derivative in
our study did not decrease the total expression of
PCNA. It may be possible that due to the cell aggregate
morphology there are different metabolic cell popula-
tions within the aggregates; cells that are at the rim are
fully exposed to nutrients and would divide faster than
cells inside the aggregates. When these aggregates are
exposed to resveratrol and acetyl-resveratrol, cell
integrity at the rim may be compromised and that may
allow nutrients to penetrate deeper inside the aggregate.
As a consequence, this will trigger cells inside the aggre-
gates to express PCNA [45]. Therefore, although there
are less cells overall in treated aggregates, PCNA may be
expressed by cells further inside the smaller aggregates
compared to the large control aggregates, thus, PCNA
appears to be unchanged after treatment.
The pathogenesis of ovarian cancer is dependent on
various molecules present in peritoneal fluid. VEGF is a
key regulator of angiogenesis, a physiological process
that is very important to cancer survival, which is associ-
ated with cell proliferation [7] and migration [46]. VEGF
is highly expressed by ovarian cancer and bystander cells
and its concentration is associated with tumour aggres-
sion and a poor prognosis [34], as such it is implicated
in ovarian cancer pathology. The current study mea-
sured the expression of VEGF after treatments with res-
veratrol and acetyl-resveratrol and found that the VEGF
production from SKOV-3 cell aggregates was attenuated
Fig. 6 Western blot analysis of SKOV-3 aggregates (a) and OVCAR-5 clusters (b) treated with resveratrol for 6 days. Densitometry ratios relative to
GAPDH of pNF-κB, NF-κB, pIκBα and PCNA of SKOV-3 aggregates (c, d, e and f) and of OVCAR-5 clusters (g, h, i and j). * indicates statistical significance
p < 0.05 compared to the control. n = 4 independent experiments in triplicate. GAPDH expression is a house keeping protein (k)
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Fig. 7 Western blot analysis of SKOV-3 aggregates (a) treated with acetyl-resveratrol for 6 days. Densitometry ratios relative to GAPDH of
pNF-κB (b), NF-κB (c), pIκBα (d) and PCNA (e). * indicates statistical significance p < 0.05 compared to the control. n = 4 independent
experiments in triplicate
Fig. 8 Treatment of SKOV-3 aggregates and OVCAR-5 clusters with Bay 11-7085. Cellular metabolism (a) and cell growth (b) are relative to control
after 6 days treatment. The secretion of VEGF (c) and IL-8 (d) measured after 6 days of treatment. * indicates statistical significance p < 0.05 compared
to the control. n = 4 independent experiments in triplicate
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by both compounds. The decrease in VEGF secretion
correlates with the time- and dose-dependent growth re-
striction of SKOV-3, this result is in accordance with
previous monolayer studies [47–49]. The level of VEGF
secretion by OVCAR-5 was, however, very low (on aver-
age 8-fold less than SKOV-3) and unaffected by the
treatments. This difference between cell lines, although
not exclusively studied before, was not totally unex-
pected. The cell lines were chosen as they have different
receptors for adhesion [50] and have different morph-
ology when grown as a monolayer or as 3D cell aggre-
gates or clusters. SKOV-3 cells form large dense
aggregates, whereas OVCAR-5 cells form small clusters.
The distinct morphology of the cell lines in the 3D
model may contribute to the activation of signalling
molecules that associate with the transcriptional profile
of VEGF.
Unexpectedly the secretion response of IL-8 is the re-
verse of VEGF. IL-8 is a cytokine that under normal
conditions is involved in the inflammatory process,
where it attracts and activates neutrophils at the site of
infection [35], and is also a potent promoter of angio-
genesis [51]. Both of these processes are keys to cancer
cell survival and metastasis. Furthermore, IL-8 has been
shown to have these effects in ovarian cancer [36, 52].
Huang et al. [53] indicated that VEGF and IL-8 secretion
are closely correlated and even potentially controlled by
the same intracellular signalling pathway. Additional
studies even suggest that IL-8 controls the expression of
VEGF [54]. However, the effect we elicited on IL-8 with
resveratrol and acetyl-resveratrol is contrary to these
suppositions. The increased secretion of IL-8 in response
to resveratrol has been observed before in normal hu-
man keratinocytes [55]. Potapovich et al. [55] first stimu-
lated the cells with TNFα and then challenged them
with 50 μM resveratrol and found that IL-8 secretion
was upregulated. Considering all this evidence, we
propose that resveratrol is suppressing one signalling
pathway that controls VEGF expression whilst possibly
up-regulating one that controls IL-8 expression. It is
possible that the production of IL-8 in our study condi-
tions may reflect a compensatory mechanism that the
cancer cells are using to overcome the lack of VEGF.
In an effort to elucidate the molecules or mechanism
targeted by resveratrol and acetyl-resveratrol, we
measured the expression of proteins associated with the
NF-κB signalling pathway. NF-κB is a family of 5 tran-
scription factors in mammalian cells, RelA (p65), RelB,
c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2),
which are able to form homo- and hetero-dimers [15].
The NF-κB cascade involves this family as well as the
upstream protein IκBα and toll-like receptors. Phosphor-
ylation of NF-κB is implicated to be important to the
transcription of IL-8 [56]. The NF-κB family and
signalling pathway promotes proliferation via regulation
of genes such as cyclin D1, D3, has been linked to gas-
tric [18], prostate [20] and breast malignancies [19] and
has been studied extensively in lymphomas [57–59]. Our
data shows that the NF-κB protein is attenuated by res-
veratrol and acetyl-resveratrol, and the expression of
NF-κB observed in the nucleus in the SKOV-3 cell ag-
gregates is markedly reduced. The phosphorylated form
of the upstream protein IκBα was unaffected. We have
also shown via NF-κB inhibition that the NF-κB protein
is involved in the cell growth and secretion of VEGF of
the cell lines. The inhibition of NF-κB was twice as
effective as resveratrol in reducing cell metabolism,
growth and VEGF secretion of the SKOV-3 aggregates
suggesting that resveratrol may not be a single action
compound, this is further supported by the opposing
trends of IL-8 secretion between resveratrol and the NF-
κB inhibitor. In OVCAR-5 cell clusters, NF-κB expres-
sion is very low and rarely visualized in the nucleus,
whilst pNF-κB was below detectable levels, the cell
growth was reduced by NF-κB inhibition, however, to a
much lesser extent than the SKOV-3 aggregates. Taken
together, these results may suggest that resveratrol and
acetyl-resveratrol may attenuate the secretion of VEGF
via the reduction of NF-κB protein level. It is possible
that resveratrol and acetyl-resveratrol may be affecting
the NF-κB protein at the transcriptional level. The
present study is limited given the lack of growth effects
of resveratrol and its derivative in normal ovarian epi-
thelial cells.
Conclusion
Taken together, our results suggest that resveratrol and
acetyl-resveratrol may exhibit anti-ovarian cancer prop-
erties through the inhibition of NF-κB. The polyphenols
were able to reduce the growth of 3D ovarian cancer
cells in a cell line-, concentration- and time-dependant
manner. This growth restriction correlated with reduc-
tion and reduced nuclear localisation of the NF-κB pro-
tein. The reduction of NF-κB in turn correlated with the
attenuation of VEGF secretion. Further studies of the
anti-ovarian cancer growth activity of resveratrol and
acetyl-resveratrol are warranted especially using in vivo
animal models before clinical trials.
Acknowledgements
We thank Health Research Council (HRC), New Zealand for Alex Tino’s
scholarship.
The authors declare that the work described has not been published
previously.
Funding
This study was partly funded by Ovarian Cancer Research Foundation (OCRF),
Melbourne, Australia.
Tino et al. Journal of Ovarian Research  (2016) 9:84 Page 10 of 12
Availability of data and materials
The data supporting the conclusion of this article is included within the
article.
Authors’ contributions
AT did experiments and prepared a manuscript. KC assisted with
experiments and prepared a manuscript. PS assisted with manuscript
preparation. AG assisted with experimental design and prepared
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Obstetrics and Gynaecology, University of Otago,
Christchurch, 2 Riccarton Avenue, Christchurch 8011, New Zealand.
2Obstetrics and Gynaecology Department Christchurch Women’s Hospital,
Private Bag 4711, Christchurch 8140, New Zealand. 3School of Biological
Sciences, University of Canterbury, Private Bag 4800, Christchurch 8140, New
Zealand.
Received: 25 May 2016 Accepted: 26 November 2016
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.:
GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC
CancerBase No. 11. 2013. Available from: globocan iarc fr. 2014.
2. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new
opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28.
3. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian
cancer. Obstet Gynecol. 2006;107(6):1399–410.
4. Dembo AJ, Dave M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic
factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol.
1990;75(2):263–73.
5. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal
interconversions in normal ovarian surface epithelium and ovarian
carcinomas: an exception to the norm. J Cell Physiol. 2007;213(3):581–8.
6. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC.
Bioengineered 3D platform to explore cell-ECM interactions and drug
resistance of epithelial ovarian cancer cells. Biomaterials. 2010;31(32):
8494–506.
7. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial
growth factor (VEGF) is an autocrine growth factor for VEGF receptor–
positive human tumors. Blood J Am Soc Hematol. 2001;98(6):1904–13.
8. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi C,
Detmar M. Stimulation of endothelial cell migration by vascular permeability
factor/vascular endothelial growth factor through cooperative mechanisms
involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol.
1996;149(1):293.
9. Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, et
al. The expression of vascular endothelial growth factor and transforming
growth factor-[beta] associates with angiogenesis in epithelial ovarian
cancer. Int J Gynecol Pathol. 1997;16(3):256–62.
10. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly
elevated levels of vascular endothelial growth factor in malignant ascites.
Ann Surg Oncol. 1999;6(4):373–8.
11. Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, et al.
Differential expression of IL-8 and IL-8 receptors in benign, borderline
and malignant ovarian epithelial tumours. Cytokine. 2013;64(1):413–21.
12. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam EE-d. Vascular
endothelial growth factor and interleukin-8 are associated with poor
prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5):
363–9.
13. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, et al.
Identification of biologically active chemokine isoforms from ascitic fluid
and elevated levels of CCL18/pulmonary and activation-regulated
chemokine in ovarian carcinoma. J Biol Chem. 2002;277(27):24584–93.
14. Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, et al. Ginger
inhibits cell growth and modulates angiogenic factors in ovarian cancer
cells. BMC Complement Altern Med. 2007;7(1):1.
15. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and
progression of human cancer. Virchows Arch. 2005;446(5):475–82.
16. De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini M, Di Fusco D, et
al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and
NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34(27):
3493–503.
17. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al.
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of
breast cancer. J Clin Investig. 1997;100(12):2952.
18. Xia J, Chen L, Jian W, Wang K-B, Yang Y, He W, et al. MicroRNA-362 induces
cell proliferation and apoptosis resistance in gastric cancer by activation of
NF-κB signaling. J Transl Med. 2014;12(1):33.
19. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ. Leptin
upregulates VEGF in breast cancer via canonic and non-canonical signalling
pathways and NFκB/HIF-1α activation. Cell Signal. 2010;22(9):1350–62.
20. Hirsch J, Johnson CL, Nelius T, Kennedy R, de Riese W, Filleur S. PEDF inhibits
IL8 production in prostate cancer cells through PEDF receptor/phospholipase
A2 and regulation of NFκB and PPARγ. Cytokine. 2011;55(2):202–10.
21. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP.
Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17
modulation. Inflammation. 2012;35(1):240–8.
22. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection
by resveratrol: A human clinical trial in patients with stable coronary artery
disease. Clin Hemorheol Microcirc. 2012;50(3):179–87.
23. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention.
Ann N Y Acad Sci. 2011;1215(1):1–8.
24. Benitez DA, Hermoso MA, Pozo‐Guisado E, Fernández‐Salguero PM,
Castellón EA. Regulation of cell survival by resveratrol involves inhibition
of NFκB regulated gene expression in prostate cancer cells. Prostate. 2009;
69(10):1045–54.
25. Karthikeyan S, Hoti SL, Prasad NR. Resveratrol loaded gelatin nanoparticles
synergistically inhibits cell cycle progression and constitutive NF-kappaB
activation, and induces apoptosis in non-small cell lung cancer cells.
Biomed Pharmacother. 2015;70:274–82.
26. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, et al. Hypoxia enhances
LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol.
Cancer Lett. 2007;258(1):63–9.
27. Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, et al.
Resveratrol has inhibitory effects on the hypoxia-induced inflammation and
angiogenesis in human adipose tissue in vitro. Eur J Pharm Sci. 2013;49(2):
251–7.
28. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215(1):9–15.
29. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo
evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
30. Colin D, Gimazane A, Lizard G, Izard JC, Solary E, Latruffe N, et al. Effects of
resveratrol analogs on cell cycle progression, cell cycle associated proteins
and 5fluoro‐uracil sensitivity in human derived colon cancer cells. Int J
Cancer. 2009;124(12):2780–8.
31. Liang L, Liu X, Wang Q, Cheng S, Zhang S, Zhang M. Pharmacokinetics,
tissue distribution and excretion study of resveratrol and its prodrug 3,5,4′-
tri-O-acetylresveratrol in rats. Phytomedicine. 2013;20(6):558–63.
32. Hogg SJ, Chitcholtan K, Hassan W, Sykes PH, Garrill A. Resveratrol, acetyl-
resveratrol and polydatin exhibit anti-growth activity against 3D cell
aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstet
Gynecol Int. 2015;2015:14.
33. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and
therapy of cancer metastasis. Cell. 1994;79(2):185–8.
34. Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C)
as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS
One. 2013;8(2):e55309.
35. Matsukawa A, Yoshimura T, Maeda T, Ohkawara S, Takagi K, Yoshinaga M.
Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8
induces destruction of cartilage and production of IL-1 and IL-1 receptor
antagonist in vivo. J Immuno. 1995;154(10):5418–25.
Tino et al. Journal of Ovarian Research  (2016) 9:84 Page 11 of 12
36. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith
M, et al. Stress effects on FosB-and interleukin-8 (IL8)-driven ovarian cancer
growth and metastasis. J Biol Chem. 2010;285(46):35462–70.
37. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and
IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(210):
1471–2407.
38. Dann JM, Sykes PH, Mason DR, Evans JJ. Regulation of vascular endothelial
growth factor in endometrial tumour cells by resveratrol and EGCG.
Gynecol Oncol. 2009;113(3):374–8.
39. Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, et al. Resveratrol inhibits invasion
and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-
catenin signal pathway. PLoS One. 2013;8(11):e78700.
40. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces
growth inhibition, S-phase arrest, apoptosis, and changes in biomarker
expression in several human cancer cell lines. Clin Cancer Res. 2002;8(3):
893–903.
41. Selvaraj S, Sun Y, Sukumaran P, Singh BB. Resveratrol activates autophagic
cell death in prostate cancer cells via downregulation of STIM1 and the
mTOR pathway. Mol Carcinog. 2015;55(5):818–31.
42. Gwak H, Kim S, Dhanasekaran DN, Song YS. Resveratrol triggers ER stress-
mediated apoptosis by disrupting N-linked glycosylation of proteins in
ovarian cancer cells. Cancer Lett. 2016;371(2):347–53.
43. Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, et al.
Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-
3 ovarian cancer cells. Mol Biosyst. 2012;8(4):1078–87.
44. Zhong L-X, Li H, Wu M-L, Liu X-Y, Zhong M-J, Chen X-Y, et al. Inhibition of
STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian
cancer cells. J Ovarian Res. 2015;8(1):1.
45. Chitcholtan K, Sykes P, Evans J. The resistance of intracellular mediators to
doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.
J Transl Med. 2012;10:38.
46. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem
cell-derived interleukin-6 and vascular endothelial growth factor promote
breast cancer cell migration. J Cell Biochem. 2012;113(11):3363–70.
47. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, et al. Resveratrol induces
apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro
and inhibits tumor growth in vivo. Cancer Sci. 2010;101(2):488–93.
48. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with
HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-
angiogenic responses in vitro and in vivo. J Biol Chem. 2011;286(15):
13626–37.
49. Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic
effects of resveratrol mediated by decreased VEGF and increased TSP1
expression in melanoma-endothelial cell co-culture. Angiogenesis. 2010;
13(4):305–15.
50. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz PN. CD44 and B1
Integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial
cells. Am J Pathol. 1999;154(5):1525–37.
51. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al.
Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science.
1992;258:1798–801.
52. Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, et al. Regulatory effect of E2,
IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol
Immunol. 2005;2(5):365–72.
53. Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ. Blockade of
nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of
human ovarian cancer cells by suppressing expression of vascular
endothelial growth factor and interleukin 8. Cancer Res. 2000;60(19):5334–9.
54. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial
growth factor (VEGF) expression and the autocrine activation of VEGFR2 in
endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1)
complex. J Biol Chem. 2009;284(10):6038–42.
55. Potapovich AI, Lulli D, Fidanza P, Kostyuk VA, De Luca C, Pastore S, et al.
Plant polyphenols differentially modulate inflammatory responses of human
keratinocytes by interfering with activation of transcription factors
NFkappaB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011;
255(2):138–49.
56. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al.
RelA Ser276 phosphorylation is required for activation of a subset of NF-κB-
dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1
complexes. Mol Cell Biol. 2008;28(11):3623–38.
57. Hathcock KS, Padilla-Nash HM, Camps J, Shin D-M, Triner D, Shaffer AL, et al.
ATM deficiency in absence of T cells promotes development of NF-kB-
dependent murine B cell lymphomas that resemble human ABC DLBCL.
Blood. 2015:blood-2015-06-654749.
58. Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, et al.
Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in
primary CNS lymphoma. Acta Neuropathol. 2010;120(4):529–35.
59. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer.
Oncogene. 1999;18(49):6938–47.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tino et al. Journal of Ovarian Research  (2016) 9:84 Page 12 of 12
